JG
ESPR

Joel Greenblatt’s Esperion Therapeutics ESPR Stock Holding History

Joel Greenblatt’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-208,451
Closed -$571K – 1835
2026
Q1 		$571K Buy
+208,451
New +$660K ﹤0.01% 1456
2025
Q1 		– Sell
-11,977
Closed -$26.3K – 1587
2024
Q4 		$26.3K Sell
11,977
-11,889
-50% -$27.7K ﹤0.01% 1420
2024
Q3 		$39.4K Buy
23,866
+8,595
+56% +$17.4K ﹤0.01% 1395
2024
Q2 		$33.9K Buy
+15,271
New +$35.9K ﹤0.01% 1401
2020
Q4 		– Sell
-20,574
Closed -$765K – 1030
2020
Q3 		$765K Buy
+20,574
New +$815K 0.02% 624
2019
Q3 		– Sell
-11,416
Closed -$531K – 1123
2019
Q2 		$531K Buy
+11,416
New +$536K 0.01% 788

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Joel Greenblatt's ESPR Position: Q2 2026 in Review

Joel Greenblatt sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 208,451 shares — an estimated $571K sold.

Joel Greenblatt first reported a position in ESPR in Q2 2019 and held it in 6 quarters. The position peaked at $765K in Q3 2020. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Joel Greenblatt reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Joel Greenblatt sold 208,451 Esperion Therapeutics shares in Q2 2026, an estimated $571K.
  • Joel Greenblatt first reported a position in Esperion Therapeutics in Q2 2019 and held it in 6 quarters.
  • Joel Greenblatt's Esperion Therapeutics position peaked at $765K in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.